The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai, MD, of the Feinstein Institute of Medical Research, Manhasset, NY, gives us a perceptive insight into advancements in the treatment of chronic lymphocytic leukemia (CLL) over recent years. Prof. Rai highlights BTK inhibitors such as ibrutinib, the BCL-2 inhibitor venetoclax, and anti-CD20 antibodies like rituximab and obinutuzumab, before giving his perspective on the potential of CAR T-cells in this space. This interview recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
